TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15598939

Group type: EXPERIMENTAL
Intervention: TAC (docetaxel 75 mg/m(2), doxorubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2) every 21 days)
Number of subjects: 285

Group type: COMPARATOR
Intervention: NX (vinorelbine 25 mg/m(2) days 1 and 8, capecitabine 2000 mg/m(2) days 1‐14, every 21 days)
Number of subjects: 285
Study: 12680746

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 10736083

Group type: EXPERIMENTAL
Intervention: Rectal codeine phosphate (1 mg.kg‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intramuscular codeine phosphate (1 mg.kg‐1)
Number of subjects: 20
Study: 8706304

Group type: EXPERIMENTAL
Intervention: GH alone (32 children)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GH plus oxandrolone (8 children)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GH plus testosterone (4 children)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (6 children)
Number of subjects: 50
Study: 1439070

Group type: EXPERIMENTAL
Intervention: Isosorbide 5‐Mononitrate 50 mg sustained release administered once daily
Number of subjects: 10
Study: 3510797

Group type: COMPARATOR
Intervention: Ketorolac 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketorolac 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen 500 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketorolac (5 mg, 10 mg)
Number of subjects: 0
Study: 31522153

Group type: EXPERIMENTAL
Intervention: Combined orthodontic regenerative therapy with laser irradiation (Group I: test group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Combined orthodontic regenerative therapy alone (Group II: control group)
Number of subjects: 15
Study: 29921056

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (parrixibub sodium 40 mg intravenously 0.5 h before surgery, oxygen budesonide aerosol inhalation therapy after surgery, sodium aescinate 10 mg intravenously at 24, 48, 72 h after surgery)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Number of subjects: 90
Study: 27196567

Group type: EXPERIMENTAL
Intervention: Oral ixazomib 3 mg
Number of subjects: 41
Study: 23231377

Group type: EXPERIMENTAL
Intervention: Nintendo Wii balance training
Number of subjects: 3

Group type: COMPARATOR
Intervention: Traditional balance therapy
Number of subjects: 3
Study: 22130395

Group type: EXPERIMENTAL
Intervention: Recovery after a maximal 30‐second sprint with rest intervals of 5, 10, 20, 40, 80, and 160 seconds
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Recovery after a maximal 30‐second sprint
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Perceived recovery via visual analog scales
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Perceived recovery
Number of subjects: 17
Study: 20668969

Group type: EXPERIMENTAL
Intervention: Mini-incision posterior approach
Number of subjects: 72

Group type: COMPARATOR
Intervention: Two-incision approach
Number of subjects: 72
Study: 17346333

Group type: EXPERIMENTAL
Intervention: Stepped-care programme for prevention of depressive and anxiety disorders
Number of subjects: 0
Study: 16137243

Group type: EXPERIMENTAL
Intervention: Concurrent calculation task
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Concurrent language task
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Concurrent motor task
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Visual cues
Number of subjects: 32
Study: 11887047

Group type: EXPERIMENTAL
Intervention: Tepid blood cardioplegia with mild systemic hypothermia (33 degrees C)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Cold blood cardioplegia with moderate systemic hypothermia (27 degrees C)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both strategies of myocardial protection
Number of subjects: 154
Study: 10094221

Group type: EXPERIMENTAL
Intervention: Suplatast tosilate and bufexamac ointment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bufexamac ointment (Control)
Number of subjects: 32
Study: 7785162

Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation (ILR)
Number of subjects: 16
Study: 2276321

Group type: EXPERIMENTAL
Intervention: 600 mg calcium supplementation
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 6776555

Group type: EXPERIMENTAL
Intervention: Ventilated cigarette holders with varying tobacco product concentrations (100% to 10%)
Number of subjects: 0
Study: 30998747

Group type: EXPERIMENTAL
Intervention: 81mg of aspirin + 400mcg of folic acid
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Placebo + 400mcg of folic acid
Number of subjects: 1228
Study: 27267403

Group type: COMPARATOR
Intervention: DDX58_rs10813831 T-allele in EBV-positive cHL patients
Number of subjects: 275

Group type: COMPARATOR
Intervention: Stratified analysis of DDX58_rs10813831 T-allele
Number of subjects: 275
Study: 25542911

Group type: EXPERIMENTAL
Intervention: E-cigarette users
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 2123
Study: 24512527

Group type: EXPERIMENTAL
Intervention: 6 months i.m. leuprorelin (androgen suppression) before radiotherapy
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: 18 months zoledronic acid (ZdA)
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: 6 and 18 months of androgen suppression (AS)
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Androgen suppression duration
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZdA)
Number of subjects: 1071
Study: 22350761

Group type: EXPERIMENTAL
Intervention: Pharmacist-assisted medication reconciliation
Number of subjects: 423
Study: 21147705

Group type: EXPERIMENTAL
Intervention: Mixed fiber diet
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-fiber diet
Number of subjects: 34
Study: 17991555

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Timed voiding (Control)
Number of subjects: 121
Study: 15663545

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bicarbonate hemodialysis (BCD)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 8
Study: 11950246

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9788453

Group type: EXPERIMENTAL
Intervention: Alteplase (0.9 mg/kg bodyweight)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 7622291

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (20% of total caloric intake from fat)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (38% of caloric intake as fat, no dietary changes)
Number of subjects: 101
Study: 2523870

Group type: EXPERIMENTAL
Intervention: ramipril (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: captopril (12.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 12
Study: 6256510

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no levamisole)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Levamisole stimulation in rats
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combination of active immunization and adjuvant stimulation with bacillus Calmette-Guerin plus levamisole
Number of subjects: 102
Study: 31069457

Group type: EXPERIMENTAL
Intervention: Total fat intake (highest versus lowest tertile)
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Substituting polyunsaturated fats with monounsaturated fats while maintaining total fat intake
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Moderate intake of monounsaturated fatty acids
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: High intake of monounsaturated fatty acids
Number of subjects: 1181
Study: 30481720

Group type: EXPERIMENTAL
Intervention: Multiplex microarray-based component resolved diagnosis (CRD) using ISAC
Number of subjects: 57

Group type: COMPARATOR
Intervention: Singleplex ImmunoCAP
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ISAC
Number of subjects: 57
Study: 27743855

Group type: EXPERIMENTAL
Intervention: Home-based exercise program, three times per week for eight weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Experimental group (EG)
Number of subjects: 32
Study: 25997548

Group type: EXPERIMENTAL
Intervention: NRL972 (Fluorescein Lisicol) 2 mg IV injection
Number of subjects: 55
Study: 23552786

Group type: EXPERIMENTAL
Intervention: Quality scale for removable partial dentures (RPD) applied by technicians familiar with the scale.
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group with no feedback information provided.
Number of subjects: 4
Study: 20093968

Group type: EXPERIMENTAL
Intervention: Cycle sprints before UPLS workout
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cycle sprints before LPUS workout
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control sessions (no sprints)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lower-body cycle sprint
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Upper-body cycle sprint
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of workout differences in Sal-T and Sal-C concentrations
Number of subjects: 30
Study: 19383227

Group type: EXPERIMENTAL
Intervention: Double aortic clamping (group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Single aortic clamping (group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (double and single clamping)
Number of subjects: 120
Study: 19690247

Group type: EXPERIMENTAL
Intervention: IBW (Ideal Body Weight) group, n = 17
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CBW20% (Corrected Body Weight plus 20% of excess weight) group, n = 17
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CBW40% (Corrected Body Weight plus 40% of excess weight) group, n = 17
Number of subjects: 51

Group type: COMPARATOR
Intervention: IBW group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 51
Study: 15195596

Group type: EXPERIMENTAL
Intervention: IgY stomat-spray (30 doses, 6 times daily, titer = 512)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IgY stomat-spray (open label trial)
Number of subjects: 50
Study: 11773155

Group type: EXPERIMENTAL
Intervention: Nausea/Vomiting (N/V) burden estimation using LASA indicators
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Overall treatment burden estimation using LASA indicators
Number of subjects: 249
Study: 9404372

Group type: EXPERIMENTAL
Intervention: Frusemide (4 ml x 10 mg/ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 12
Study: 8256357

Group type: EXPERIMENTAL
Intervention: Personalized hospital practice (PHP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard hospital practice (Control)
Number of subjects: 100
Study: 3442947

Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study: 11519503

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg immediately, followed by 75 mg once daily)
Number of subjects: 12562

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12562
Study: 31368137

Group type: EXPERIMENTAL
Intervention: Continuous care using mobile health application
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 120
Study: 29937253

Group type: EXPERIMENTAL
Intervention: Links to Learning (L2L) model for referred, disruptive students
Number of subjects: 136

Group type: COMPARATOR
Intervention: Services and professional development as usual (SAU)
Number of subjects: 136
Study: 26907087

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM) 2g daily for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM) 4g daily for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM) 10g daily for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall sample (CM and placebo)
Number of subjects: 0
Study: 24812104

Group type: EXPERIMENTAL
Intervention: CICADA method
Number of subjects: 162
Study: 22634536

Group type: EXPERIMENTAL
Intervention: RHES+radiotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 50
Study: 20433803

Group type: EXPERIMENTAL
Intervention: FSME-IMMUN Junior
Number of subjects: 303

Group type: COMPARATOR
Intervention: Encepur Children
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 303
Study: 17631129

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 434

Group type: COMPARATOR
Intervention: White Light
Number of subjects: 434
Study: 15728066

Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia
Number of subjects: 3261

Group type: EXPERIMENTAL
Intervention: Preemptive local anesthetic wound infiltration
Number of subjects: 3261

Group type: EXPERIMENTAL
Intervention: Preemptive NSAID administration
Number of subjects: 3261

Group type: EXPERIMENTAL
Intervention: Systemic NMDA antagonist
Number of subjects: 3261

Group type: EXPERIMENTAL
Intervention: Systemic opioid administration
Number of subjects: 3261
Study: 11804984

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg per os per day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg per os per day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of estrogens and ramipril
Number of subjects: 19
Study: 10359888

Group type: EXPERIMENTAL
Intervention: Aggressive intervention for dust mite elimination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard environmental control intervention
Number of subjects: 0
Study: 7677236

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 0
Study: 1646194

Group type: COMPARATOR
Intervention: Thoracic megavoltage radiotherapy alone (65 Gy in 26 fractions over 45 days)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Thoracic megavoltage radiotherapy preceded and followed by 3 monthly cycles of VCPC (vindesine 1.5 mg/m2 d 1‐2, cyclophosphamide 200 mg/m2 d 2‐4, cisplatinum 100 mg/m2 d 2, lomustine 75 mg/m2 d 3)
Number of subjects: 353
Study: 7025235

Group type: EXPERIMENTAL
Intervention: T-N/10 HCl perfusion
Number of subjects: 64

Group type: COMPARATOR
Intervention: N/10 HCl perfusion
Number of subjects: 64
Study: 30586700

Group type: EXPERIMENTAL
Intervention: Oral Anticoagulation (OAC) alone
Number of subjects: 696

Group type: COMPARATOR
Intervention: Combined OAC and single Antiplatelet Therapy (APT)
Number of subjects: 696
Study: 27475283

Group type: EXPERIMENTAL
Intervention: C. vulgaris (four 300 mg tablets)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (four 300 mg tablets)
Number of subjects: 70
Study: 26202179

Group type: COMPARATOR
Intervention: Sildenafil therapy
Number of subjects: 0
Study: 25029833

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no transcutaneous electrical nerve stimulation)
Number of subjects: 60
Study: 21909049

Group type: EXPERIMENTAL
Intervention: PHiD‐CV
Number of subjects: 52

Group type: COMPARATOR
Intervention: 7vCRM
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Additional PCV dose
Number of subjects: 52
Study: 19651272

Group type: EXPERIMENTAL
Intervention: FES leg cycling exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Passive leg cycling
Number of subjects: 30

Group type: COMPARATOR
Intervention: Electrical stimulation therapy (noncycling control group)
Number of subjects: 30
Study: 17477777

Group type: EXPERIMENTAL
Intervention: Psychosocial stressors (family stressors)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Lower income
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Working at a job
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 101
Study: 16314627

Group type: EXPERIMENTAL
Intervention: Low-dose leucovorin plus fluorouracil (Mayo Clinic; LDLV) regimen for 30 to 32 weeks
Number of subjects: 3794

Group type: EXPERIMENTAL
Intervention: High-dose leucovorin plus fluorouracil (Roswell Park; HDLV) regimen for 30 to 32 weeks
Number of subjects: 3794

Group type: EXPERIMENTAL
Intervention: Low-dose leucovorin plus levamisole plus fluorouracil (LDLV plus LEV) regimen for 30 to 32 weeks
Number of subjects: 3794

Group type: COMPARATOR
Intervention: Levamisole plus fluorouracil (LEV) for 1 year
Number of subjects: 3794

Group type: EXPERIMENTAL
Intervention: Overall survival and disease-free survival across all treatment arms
Number of subjects: 3794
Study: 11571954

Group type: EXPERIMENTAL
Intervention: Misgav Ladach procedure
Number of subjects: 160

Group type: COMPARATOR
Intervention: Traditional CS
Number of subjects: 160
Study: 9630000

Group type: EXPERIMENTAL
Intervention: Quetiapine 225 mg bd
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Quetiapine 150 mg tid
Number of subjects: 618

Group type: COMPARATOR
Intervention: Quetiapine 50 mg bd
Number of subjects: 618
Study: 7875268

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3345339

Group type: EXPERIMENTAL
Intervention: Nifedipine (orally administered)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (untreated stable sickle cell subjects)
Number of subjects: 11
Study: 31726472

Group type: EXPERIMENTAL
Intervention: Warmed and humidified carbon dioxide (W-H-CO2) insufflation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no W-H-CO2)
Number of subjects: 50
Study: 28598560

Group type: EXPERIMENTAL
Intervention: Tourniquet group (TG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-tourniquet group (NG)
Number of subjects: 52
Study: 26614142

Group type: EXPERIMENTAL
Intervention: Intrathecal 2.5mg hyperbaric levobupivacaine plus 12.5 μg fentanyl
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intrathecal 2.5mg hyperbaric levobupivacaine plus 25 μg fentanyl
Number of subjects: 52
Study: 23218892

Group type: EXPERIMENTAL
Intervention: L‐methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal‐5'‐phosphate 35 mg
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 21621169

Group type: COMPARATOR
Intervention: Institutional-based therapy (IT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: IT plus structured home activity program (HAP)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: HAP
Number of subjects: 70
Study: 19469703

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Unsupervised artemether-lumefantrine (AL)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Unsupervised artesunate-amodiaquine (ASAQ)
Number of subjects: 240
Study: 16404099

Group type: EXPERIMENTAL
Intervention: Mobile narratives (MN)
Number of subjects: 33

Group type: COMPARATOR
Intervention: New age music and videos (NA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No treatment (CT)
Number of subjects: 33
Study: 15547070

Group type: EXPERIMENTAL
Intervention: Self assessed health measure before screening
Number of subjects: 23654

Group type: EXPERIMENTAL
Intervention: Self assessed health measure after screening
Number of subjects: 23654
Study: 10836913

Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin, 25 microg/kg per day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin, 100 microg/kg per day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 8770972

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (2 micrograms) and 3.5 mEq/liter calcium dialysate for six weeks
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 4 mEq/liter calcium dialysate and increased oral calcium supplementation for six weeks
Number of subjects: 2
Study: 1460407

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine
Number of subjects: 0
Study: 6361099

Group type: COMPARATOR
Intervention: Medical therapy (control group)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Surgical therapy (intervention group)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Medical therapy (randomizable group)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Surgical therapy (randomizable group)
Number of subjects: 780
Study: 30698487

Group type: EXPERIMENTAL
Intervention: 12.5 mg/mL pirfenidone solution
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 100 mg pirfenidone
Number of subjects: 44
Study: 30833215

Group type: EXPERIMENTAL
Intervention: cathodal HD-tDCS to inhibit the vlPFC
Number of subjects: 52

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: cathodal HD-tDCS to inhibit the dmPFC
Number of subjects: 52
Study: 28985109

Group type: EXPERIMENTAL
Intervention: Liquid Alpha1‐PI
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lyophilized Alpha1‐PI
Number of subjects: 32
Study: 25892175

Group type: EXPERIMENTAL
Intervention: RELATE with Couple CARE (RCC)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Couple Coping Enhancement Training (CCET)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 301
Study: 23688180

Group type: COMPARATOR
Intervention: SB + PA (combined sedentary behavior and physical activity intervention)
Number of subjects: 293

Group type: COMPARATOR
Intervention: SB (sedentary behavior intervention)
Number of subjects: 293

Group type: COMPARATOR
Intervention: All intervention groups (SB, PA, SB + PA)
Number of subjects: 293
Study: 21560124

Group type: EXPERIMENTAL
Intervention: Tutorial teaching orientation strategies at specific stages of laparoscopic cholecystectomy
Number of subjects: 30